Recommendations for the Use of Prolonged-Release Fampridine in Patients with Multiple Sclerosis (MS)

• Authors: PREININGEROVA Jana Lizrova; BAUMHACKL Ulf; CSEPANY Tunde; CZAPLINSKI Adam; DEISENHAMMER Florian; DERFUSS Tobias; FABJAN Tanja H.; FAZEKAS Franz; FUCHS Siegrid; HAVRDOVA Eva; LEDINEK Alenka Horvath; ILLES Zsolt; JAZBEC Sasa Sega; KLIMOVA Eleonora; KOMOLY Samuel; KURCA Egon; LINNEBANK Michael; LISY Lubomir; MARES Jan; PROCHAZKOVA Lubica; CSILLA Rozsa; SZILASIOVA Jarmila; ŠTOURAČ Pavel; TALAB Radomir; TURCANI Peter; VACHOVA Marta; VECSEI Laszlo; VODUSEK David; ZAPLETALOVA Olga; BERGER Thomas
• Year of publication: 2013
• Type: Article in Periodical
• Magazine / Source: CNS NEUROSCIENCE &THERAPEUTICS
• MU Faculty or unit: Central European Institute of Technology
• Doi: http://dx.doi.org/10.1111/cns.12101
• Field: Neurology, neurosurgery, neurosciences
• Keywords: Aminopyridines; Fampridine; Multiple sclerosis; Walking
• Description: Prolonged-release fampridine (fampridine PR) is a potassium channel blocker that improves conductivity of signal on demyelinated axons in central nervous system. Fampridine PR has been approved to improve speed of walking in patients with multiple sclerosis. This statement provides a brief summary of data on fampridine PR and recommendations on practical use of the medication in clinical practice, prediction, and evaluation of response to treatment and patient management.